BACKGROUND: This study defined the risk of serious toxicity in phase I trials of molecularly targeted agents (MTA). PATIENTS AND METHODS: A retrospective analysis of toxicity data from patients treated in phase I trials of MTAs was carried out to define the rate of treatment-related grade 3/4 toxic effects, deaths and risk factors associated with grade 3 or more toxicity. RESULTS: Data from 687 patients [median age, 59.1 years (range 12.5-85.5)] treated in 36 trials were analysed. Two hundred and eleven patients were of Eastern Cooperative Oncology Group performance status (PS) zero, 432 of PS one, 38 of PS two and 6 unknown. The rate of grade 3 and 4 events was 14.1% (n=97) and 1.9% (n=13), respectively. Twenty-four percent of events were gastrointestinal, 22% constitutional and 20% metabolic. PS two was associated with a higher risk of toxicity [odds ratio (OR), 2.6; 95% confidence interval (CI) 1.1-6.1; P=0.032] as was receiving >100% of maximum tolerated dose or maximum administered dose (OR 2.5; CI 1.6-3.9; P<0.001). Mortality rate was 0.43% (n=3). CONCLUSIONS: Therapy with novel MTAs in phase I trials is associated with a moderate risk of significant toxicity. This appears less than in phase I studies involving cytotoxic agents, particularly in relation to grade 4 toxicity. The risk of death is low.
BACKGROUND: This study defined the risk of serious toxicity in phase I trials of molecularly targeted agents (MTA). PATIENTS AND METHODS: A retrospective analysis of toxicity data from patients treated in phase I trials of MTAs was carried out to define the rate of treatment-related grade 3/4 toxic effects, deaths and risk factors associated with grade 3 or more toxicity. RESULTS: Data from 687 patients [median age, 59.1 years (range 12.5-85.5)] treated in 36 trials were analysed. Two hundred and eleven patients were of Eastern Cooperative Oncology Group performance status (PS) zero, 432 of PS one, 38 of PS two and 6 unknown. The rate of grade 3 and 4 events was 14.1% (n=97) and 1.9% (n=13), respectively. Twenty-four percent of events were gastrointestinal, 22% constitutional and 20% metabolic. PS two was associated with a higher risk of toxicity [odds ratio (OR), 2.6; 95% confidence interval (CI) 1.1-6.1; P=0.032] as was receiving >100% of maximum tolerated dose or maximum administered dose (OR 2.5; CI 1.6-3.9; P<0.001). Mortality rate was 0.43% (n=3). CONCLUSIONS: Therapy with novel MTAs in phase I trials is associated with a moderate risk of significant toxicity. This appears less than in phase I studies involving cytotoxic agents, particularly in relation to grade 4 toxicity. The risk of death is low.
Authors: A Schwandt; P J Harris; S Hunsberger; A Deleporte; G L Smith; D Vulih; B D Anderson; S P Ivy Journal: Clin Cancer Res Date: 2014-07-15 Impact factor: 12.531
Authors: David M Hyman; Anne A Eaton; Mrinal M Gounder; Gary L Smith; Erika G Pamer; Martee L Hensley; David R Spriggs; Percy Ivy; Alexia Iasonos Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: Mrinal M Gounder; Lakshmi Nayak; Solmaz Sahebjam; Alona Muzikansky; Armando J Sanchez; Serena Desideri; Xiaobu Ye; S Percy Ivy; L Burt Nabors; Michael Prados; Stuart Grossman; Lisa M DeAngelis; Patrick Y Wen Journal: J Clin Oncol Date: 2015-08-17 Impact factor: 44.544
Authors: Saeed Rafii; Desamparados Roda; Elena Geuna; Begona Jimenez; Karim Rihawi; Marta Capelan; Timothy A Yap; L Rhoda Molife; Stanley B Kaye; Johann S de Bono; Udai Banerji Journal: Clin Cancer Res Date: 2015-02-03 Impact factor: 12.531
Authors: Bethany Geary; Erin Peat; Sarah Dransfield; Natalie Cook; Fiona Thistlethwaite; Donna Graham; Louise Carter; Andrew Hughes; Matthew G Krebs; Anthony D Whetton Journal: Cancers (Basel) Date: 2021-05-18 Impact factor: 6.639
Authors: E Geuna; D Roda; S Rafii; B Jimenez; M Capelan; K Rihawi; F Montemurro; T A Yap; S B Kaye; J S De Bono; L R Molife; U Banerji Journal: Br J Cancer Date: 2015-11-10 Impact factor: 7.640
Authors: B Basu; J Vitfell-Pedersen; V Moreno Garcia; M Puglisi; A Tjokrowidjaja; K Shah; S Malvankar; B Anghan; J S de Bono; S B Kaye; L R Molife; U Banerji Journal: Oncology Date: 2012-08-07 Impact factor: 2.935